Explore

Cold Therapy Market Projected for Significant Growth in Pain Management Sector

Cold Therapy Market Projected for Significant Growth in Pain Management Sector

Cold Therapy Market Projected for Significant Growth in Pain Management Sector

Mizzou Alum John Ruth Drives $10 Million State Investment for Rare Disease Research, Establishes Center for Translational Neurogenetics

Mizzou Alum John Ruth Drives $10 Million State Investment for Rare Disease Research, Establishes Center for Translational Neurogenetics

John Ruth, a University of Missouri (Mizzou) alumnus, has spearheaded a significant initiative resulting in a $10 million investment from the state of Missouri to fund research into rare genetic disorders. This funding has led to the establishment of the Center for Translational Neurogenetics (CTN) at Mizzou. Ruth's advocacy was motivated by his daughter, Kamdyn, who was diagnosed with Baker-Gordon Syndrome, an ultra-rare neurodevelopmental disorder caused by an SYT1 gene mutation. Through the Genetic Autism Alliance, an independent nonprofit he founded, Ruth championed the cause for increased research into such conditions, which often lack private industry investment due to their rarity. Mizzou researchers at the CTN have already developed a gene-editing technique called CRISPR-SWITCH, creating a preclinical model of Baker-Gordon Syndrome that more accurately reflects the human condition, offering new avenues for study and potential therapeutic development.

Representative Buddy Carter Supports Emergency Alert Modernization and Fentanyl Detection Research

Representative Buddy Carter Supports Emergency Alert Modernization and Fentanyl Detection Research

Representative Earl L. “Buddy” Carter, a Republican from Georgia's 1st congressional district, has actively supported two key legislative initiatives. He voiced his support for the Mystic Alerts Act, a bipartisan bill aimed at updating and improving America's emergency alert systems. This legislation seeks to enhance the effectiveness and reach of alerts during critical situations, ensuring that the public receives timely and accurate information. Additionally, Representative Carter backed a congressionally directed spending award designated for Augusta University. This funding is specifically allocated for research focused on developing rapid fentanyl detection methods. Fentanyl, a potent synthetic opioid, poses a significant public health challenge, and rapid detection is crucial for intervention and prevention efforts. These actions highlight Carter's engagement in both public safety infrastructure and critical health research.

Scientists Develop Nasal Spray H5N1 Vaccine Showing Promise in Mice Against Bird Flu

Scientists Develop Nasal Spray H5N1 Vaccine Showing Promise in Mice Against Bird Flu

Scientists have developed an experimental nasal spray vaccine for the H5N1 avian influenza virus, demonstrating significant protection in mice. The vaccine, which uses a modified vesicular stomatitis virus (VSV) as a carrier to deliver H5N1-related material, was administered in two doses four weeks apart. Following exposure to a lethal strain of H5N1, all vaccinated mice survived, while unvaccinated control animals did not. Researchers observed a dramatic reduction in viral load, with approximately 100,000 times less virus found in the nasal and tracheal tissues of vaccinated mice compared to unvaccinated ones. This approach aims to stimulate mucosal immunity, providing a localized defense at the respiratory surfaces where the virus typically enters the body, rather than relying solely on systemic immunity. The protection offered by the vaccine was also found to be durable, lasting for months in the tested animals.

Thryv Therapeutics Publishes Evidence Supporting THRV-1268 for Heart Failure Treatment

Thryv Therapeutics Publishes Evidence Supporting THRV-1268 for Heart Failure Treatment

Thryv Therapeutics Inc. has announced the publication of a new study in JACC: Heart Failure, presenting human genetic, preclinical, and clinical evidence that supports the use of its lead SGK1 inhibitor, THRV-1268, for treating heart failure with reduced ejection fraction (HFrEF). The study highlights SGK1 as a genetically validated cardiometabolic therapeutic target. Key findings indicate that THRV-1268 maintained cardiac function and outperformed empagliflozin monotherapy in an animal model of heart failure. Additionally, Phase 1 studies demonstrated a favorable safety profile and statistically significant QTcF shortening in individuals with obesity, consistent with cardiac target engagement. These findings provide a strong rationale for advancing THRV-1268 into Phase 2a clinical development through the ASPIRE-HF study, which is expected to begin enrollment in Q4 2026.

FDA holds public hearing on psychedelic drugs as Trump-driven push gathers pace

FDA holds public hearing on psychedelic drugs as Trump-driven push gathers pace

By Puyaan Singh and Kamal Choudhury Sept 14 (Reuters) - The U.S.

How to treat scoliosis

How to treat scoliosis

Here’s what doctors can do about scoliosis, and what patients should expect from treatment plans.

Resistance Bands Offer Effective Lower-Body Strength Training Comparable to Weights

Resistance Bands Offer Effective Lower-Body Strength Training Comparable to Weights

Resistance Bands Offer Effective Lower-Body Strength Training Comparable to Weights

Real Salt Lake's Diego Luna to miss rest of MLS season with torn meniscus

Real Salt Lake's Diego Luna to miss rest of MLS season with torn meniscus

The 23-year-old attacker announced that his season in the MLS is over, with a return planned next year.

Ryan Williams, Director of Rehabilitation, Praises Mary Lanning Healthcare's Cardiac Rehab Recertification

Ryan Williams, Director of Rehabilitation, Praises Mary Lanning Healthcare's Cardiac Rehab Recertification

Ryan Williams, the Director of Rehabilitation at Mary Lanning Healthcare (MLH), has expressed pride in the MLH Cardiac Rehabilitation team following their recent recertification by the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR). This recertification acknowledges MLH's dedication to improving patient quality of life through enhanced care standards. The MLH Cardiac Rehabilitation team, comprising registered nurses, dietitians, a pharmacist, and a mental health practitioner, is recognized for creating personalized programs tailored to meet individual patient needs and goals. Williams highlighted that the AACVPR Program Certification is the sole peer-reviewed recertification process designed to evaluate facilities for adherence to national standards and guidelines. The program at MLH incorporates monitored exercise and heart-health education, aiming to slow disease progression, reduce the risk of future cardiac events, and support long-term wellness for patients.

Resistance Bands Offer Versatile Fitness Solutions for All Ages and Fitness Levels

Resistance Bands Offer Versatile Fitness Solutions for All Ages and Fitness Levels

Resistance Bands Offer Versatile Fitness Solutions for All Ages and Fitness Levels

Cleveland Clinic Main Campus Offers Advanced Diagnostic Services in Ohio

Cleveland Clinic Main Campus Offers Advanced Diagnostic Services in Ohio

Cleveland Clinic's Main Campus in Cleveland, Ohio, is providing a range of advanced diagnostic services. These services include DEXA Bone Density screenings for osteopenia and osteoporosis, Low-Dose CT Lung Screenings (LDCT) recommended for current and former smokers, and Coronary CT Angiograms for detailed examination of heart arteries. Additionally, the campus offers CCTA with HeartFlow FFRct to assess blood flow affected by arterial narrowing, and Breast MRI without and with contrast for breast cancer screening. Instalab facilitates the booking process for these services, handling scheduling, results delivery, and physician review. Patients can book appointments without a doctor's order, as Instalab provides the necessary physician order, and transparent upfront pricing is available.